Australia's largest stock trading and investment forum Australia's #1 stock forum

PAR

0.00%

26.5¢ paradigm biopharmaceuticals limited..

AGM 2024 - QUESTIONS, page-29

First 29 Last

Share
Profile

Follow
oxxa23

6,027 Posts.

1160

17/11/23

14:58

Post #: 70965757
Share
Originally posted by Denial ↑

Before I give this thread a break until the new year my view for Q&A is to be extremely focused given the limited time made available. Some of the above are not critical IMO and can be asked at the AGM in person after the formal meeting is closed.

Commercial deals including feedback from those signing NDA - per posted by
TanamiRod
above. I note they have changed the narrative to regional deals for MPS and now OA (China). What the hell is happening with the the main game - partnering is our target market (US, EU5)???????? Most critically has the thinking NOW changed to post 002-003 read-out and if so why given all the DMOAD data is now out? If so think about the implications and inherent risk!!!!!!!!!!!

Probability of getting dosage back to 2mg/kg x 2 week for Stage 2 - without which its GAME OVER. Forget MPS and all other side hustles as no one appears to care at this stage.

The above are existential to PAR's future and we shouldn't kid ourselves that PAR is anything other than a one man band. Yes governance is a farce but the damage is now done, inclusive of performance rights. So whilst interesting its a side issue that will only be resolved if the above 2 questions are resolved.

Expand

hi denial,

good questions no doubt... with reference to the 2mg/kg... i believe worst case they would pivot and change tact and go for europe only (not USA) if FDA didn't allow it... i think it was only USA that had concerns at all..

of course, would be far from ideal, and would waste some time rearranging, but, i dont think all would be lost...but, still want the question asked.

cheers
PAR Price at posting: 39.8¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

What's causing the cost-of-living crisis, and how to navigate it

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

TLG

Talga Group wins key permit for flagship graphite mine in Sweden